Triphenylamine compounds and preparation methods and applications thereof

Through high-throughput screening and synthesis of trianiline compounds, the problem of resistance to existing antibacterial agents was solved, and a novel antibacterial agent with effective antibacterial activity against Staphylococcus aureus, E. coli and Pseudomonas aeruginosa was developed. Fill in the gap in the new structural antibacterial agents in the prior art.

CN118440089BActive Publication Date: 2024-12-03GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410562921.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-08
Publication Date
2024-12-03
Estimated Expiration
2044-05-08

AI Technical Summary

Technical Problem

After long-term use of existing antibacterial agents, microorganisms are prone to resistance, resulting in reduced effects, and lack of new structures of antibacterial agents to cope with this challenge.

Method used

A triphenylamine compound was developed through high-throughput screening method, using diphenylamine-4-benzaldehyde, malonitrile and 1,3-dione compounds as raw materials, combining calcium carbonate, potassium carbonate or nitric acid hexahydrate as raw materials, using calcium carbonate, and nitric acid hexahydrate as raw materials. Nickel is used as a dehydrating agent or catalyst to produce a tripaniline compound by heating and stirring reaction, and serves as an active ingredient for antibacterial reagents.

Benefits of technology

The prepared trianiline compounds showed good antibacterial activity, had significant antibacterial effects on Staphylococcus aureus, E. coli and Pseudomonas aeruginosa, providing a new structure of antibacterial agent solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004828324020000011
    Figure BDA0004828324020000011
  • Figure BDA0004828324020000022
    Figure BDA0004828324020000022
  • Figure BDA0004828324020000023
    Figure BDA0004828324020000023
Patent Text Reader

Abstract

The present invention discloses triphenylamine compounds, preparation methods and applications thereof. The structural formula of the triphenylamine compounds is shown in formula (II). The present invention develops a triphenylamine compound with a new structure by a high-throughput screening method, and the preparation method thereof is as follows: using diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compound (I) as raw materials, condensing to obtain the product triphenylamine compound (II). The triphenylamine compound exhibits antibacterial activity, especially has good antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, and can be used as an antibacterial agent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antibacterial, and in particular relates to triphenylamine compounds and a preparation method and application thereof. Background Art

[0002] Bacterial infection is a common disease and a common source of material or product deterioration in industry. It poses a serious threat to human health and industrial production. Although there are several types of bactericides or agents available in medicine and industry, with the long history of use of these agents, the self-survival ability of microorganisms has led to a certain degree of drug resistance. Discovering new antibacterial / bactericides has become an important research topic in this field. High-throughput screening is one of the methods to obtain new antibacterial / bactericides. The triphenylamine compounds obtained by screening may become new antibacterial / bactericides. Summary of the invention

[0003] The first object of the present invention is to provide a triphenylamine compound or a salt thereof, wherein the structural formula of the triphenylamine compound is as shown in formula (II):

[0004]

[0005] The R is selected from

[0006] The second object of the present invention is to provide a method for preparing the above-mentioned triphenylamine compound or its salt, which comprises the following steps: using diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compound as raw materials, condensing to obtain a product triphenylamine compound (II), wherein the 1,3-diketone compound is selected from

[0007] Preferably, the method comprises the following steps: using diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compounds as raw materials, using calcium carbonate or potassium carbonate as a dehydrating agent, or using nickel nitrate hexahydrate as a catalyst, using ethanol, methanol or ethanol aqueous solution as a solvent, heating and stirring the reaction to obtain a triphenylamine compound (II), wherein the 1,3-diketone compound is selected from

[0008] Preferably, the molar ratio of the diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compound is 1:1:1; the amount of the dehydrating agent or catalyst is 3%-20% of the reaction volume ratio; and the heating and stirring reaction is a stirring reaction at 60°C-80°C.

[0009] Preferably, the synthesis reaction formula of the triphenylamine compound is:

[0010]

[0011] The preparation method of the present invention has a yield of 25% to 87%.

[0012] The third object of the present invention is to provide the use of the above-mentioned triphenylamine compounds or their salts in the preparation of antibacterial agents.

[0013] Preferably, the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

[0014] The fourth object of the present invention is to provide an antibacterial agent containing the above-mentioned triphenylamine compound or its salt as an active ingredient.

[0015] Preferably, the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

[0016] Preferably, the concentration of the triphenylamine compound or its salt is 4-16 μg / mL.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention develops a triphenylamine compound with a completely new structure by a high-throughput screening method. The preparation method of the triphenylamine compound is as follows: diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compound (I) are used as raw materials for condensation to obtain the product triphenylamine compound (II).

[0019] The triphenylamine compound synthesized by the invention is easy to synthesize and shows good antibacterial activity, and has good antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. As a triphenylamine compound with a completely new structure, it has great application value in the field of antibacterial technology. DETAILED DESCRIPTION

[0020] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.

[0021] Embodiment 1:

[0022] Preparation steps of 2-amino-4-(4-(diphenylamino)phenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carbonitrile (IIa):

[0023]

[0024] 1 mmol of diphenylamino-4-benzaldehyde, 1 mmol of malononitrile, 1 mmol of 4-hydroxycoumarin, 0.03 mmol of calcium carbonate and 40 mL of ethanol were added to a 100 mL flask, and the mixture was stirred and reacted at 70° C. for 48 hours. After the reaction was completed, the mixture was filtered, the filtrate was decompressed and dried, and the mixture was purified by silica gel column chromatography (200-300 mesh, eluent was ethyl acetate: petroleum ether (60° C.-90° C.), gradient elution: petroleum ether for 10 min, 0-20% ethyl acetate by volume for 20 min, 20% ethyl acetate by volume for 10 min, 20-100% ethyl acetate by volume for 20 min, ethyl acetate for 10 min), and the product emitting orange light under 365 nm light irradiation in the 20% ethyl acetate 10 min section was collected, and the target product (IIa) was obtained after decompression and drying. The Rf value was 0.54 (volume ratio of ethyl acetate: petroleum ether=1:1), and the yield was 25%. 1 HNMR(600MHz,DMSO-d6,δ):7.90(d,1H,benzene),7.72(t,1H,benzene),7.48(m,2H,benzene),7.39(s,2H,-NH2),7.29(t,4H,benzene ),7.16(d,2H,benzene),7.03(t,2H,benzene),6.98(d,4H,benzene),6.92(d,2H,benzene),4.41(s,1H,pyran).HRMS(ESI):m / zcalcd for C 31 H 22 N3O3 + :484.1655[M+H] + ;found:484.1654.m / z calcd for C 31 H 21 N3O3Na + :506.1475[M+Na] + ;found:506.1479.

[0025] Embodiment 2:

[0026] Preparation steps of 2-amino-4-(4-(diphenylamino)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (IIb):

[0027]

[0028] 1 mmol of diphenylamino-4-benzaldehyde, 1 mmol of malononitrile, 1 mmol of dimedone, 0.1 mmol of nickel nitrate hexahydrate, and 10 mL of ethanol / water (volume ratio 1 / 1) were added into a 30 mL reactor and stirred at 80° C. for 12 hours. After the reaction was completed, 20 mL of ice water was added to cool for 10 min, filtered, and the residue was recrystallized from ethanol to obtain the target product (IIb) with a yield of 87%. 1 H NMR(600MHz,CDCl3,δ):7.26(t,4H,benzene),7.09(m,6H,benzene),7.00(m,4H,benzene),4.54(s,2H,-NH2),4.39(s, 1H,pyran),2.28(s,2H,methylene),1.60(s,2H,methylene),1.14(s,3H,methyl),1.08(s,3H,methyl).HRMS(ESI):m / z calcd for C 30 H 28 N3O2 + :462.2176[M+H] + ;found:462.2178.m / z calcd for C 30 H 27 N3O2Na + :484.1995[M+Na] + ;found:484.2004.

[0029] Embodiment 3:

[0030] Preparation steps of 2-amino-4-(4-(diphenylamino)phenyl)-6,6-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (IIc):

[0031]

[0032] 1 mmol of diphenylamino-4-benzaldehyde, 1 mmol of malononitrile, 1 mmol of 4,4-dimethyl-1,3-cyclohexanedione, 0.2 mmol of potassium carbonate and 25 mL of methanol were added to a 100 mL flask, stirred and reacted at 60° C. for 24 hours. After the reaction was completed, the product was filtered, the filtrate was evaporated under reduced pressure, and purified by silica gel column chromatography (200-300 mesh, eluent was ethyl acetate: petroleum ether (60° C.-90° C.), gradient elution: petroleum ether for 10 min, 0-20% ethyl acetate by volume for 20 min, 20% ethyl acetate by volume for 10 min, 20-100% ethyl acetate by volume for 20 min, ethyl acetate for 10 min), the product under 20% ethyl acetate for 10 min was collected, and the target product (IIc) was obtained after reduced pressure and evaporated to dryness, with an Rf value of 0.11 (volume ratio of ethyl acetate: petroleum ether=1:3), and a yield of 46%. 1 HNMR(600MHz,CDCl3,δ):7.26(t,4H,benzene),7.09(m,6H,benzene),7.02(m,4H,benzene),4.53(s,2H,-NH2),4.38(s, 1H,pyran),1.89(s,2H,methylene),1.62(s,2H,methylene),1.12(s,3H,methyl),1.05(s,3H,methyl).HRMS(ESI):m / z calcd for C 30 H 28 N3O2 + :462.2176[M+H] + ;found:462.2188.m / z calcd for C 30 H 27 N3O2Na + :484.1995[M+Na] + ;found:484.2015.

[0033] Embodiment 4:

[0034] Antimicrobial activity test of target compounds:

[0035] The MIC of the target compound (triphenylamine compound prepared in Example 1-3) was determined by microdilution method using 2-methyl-4-isothiazolin-3-one (MIT) as a positive control agent, and the antibacterial activity of the target compound (triphenylamine compound prepared in Example 1-3) against Staphylococcus aureus (Staphylococcus aureus ATCC 6538P), Escherichia coli (Escherichia coli ATCC 8739), and Pseudomonas aeruginosa (Pseudomonas aeruginosa ATCC 9027) was determined.

[0036] The experimental steps of microdilution method are as follows:

[0037] Add 200 μL of the sample (2-methyl-4-isothiazoline-3-one (rows 1 and 5) and the triphenylamine compound prepared in Example 1-3 (rows 2-4, 6-8)) with a concentration of 256 μg / mL to the first column of the 96-well plate, add 100 μL of MH broth to columns 2-12 respectively, then take 100 μL from column 1 and add it to column 2 to mix, then take 100 μL from column 2 and add it to column 3 to mix, and so on, finally take 100 μL from column 10 and add it to column 11 to mix, then take out 100 μL of excess liquid and discard. Take 100 μL of 10 6 cfu / mL of bacterial solution was added to each well in columns 1-11, and 100 μL of the concentration of 10 6 cfu / mL of bacterial solution was added to the first four wells of the 12th column, and 100μL of MH broth was added to the last four wells of the 12th column. The final volume of each well was 200μL. The concentrations of the samples to be tested in columns 1-11 were 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125μg / mL, respectively. The first four wells of the 12th column were bacteria-free (bacterial growth control), and the last four wells of the 12th column were bacteria-free (blank sterile control). Three replicates were made for each sample to be tested. After the 96-well plate was incubated in a 37°C oven for 24 hours, the OD was measured using an enzyme reader. 600 Value, OD 600 The concentration of the wells with values ​​close to the sterile control is the minimum inhibitory concentration (MIC).

[0038] The results show:

[0039] (1) The MICs of 2-amino-4-(4-(diphenylamino)phenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carbonitrile (IIa) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 8μg / mL, 8μg / mL, and 16μg / mL, respectively.

[0040] (2) The MICs of 2-amino-4-(4-(diphenylamino)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (IIb) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 4 μg / mL, 8 μg / mL, and 8 μg / mL, respectively.

[0041] (3) The MICs of 2-amino-4-(4-(diphenylamino)phenyl)-6,6-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (IIc) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 4 μg / mL, 4 μg / mL, and 8 μg / mL, respectively.

[0042] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.

Claims

1. A triphenylamine compound or a salt thereof, wherein the triphenylamine compound has a structural formula as shown in formula (II): The R is selected from 2. A method for preparing the triphenylamine compound or its salt according to claim 1, characterized in that: The steps include: Using diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compounds as raw materials, calcium carbonate or potassium carbonate as a dehydrating agent, ethanol or methanol as a solvent, heating and stirring to react, to obtain triphenylamine compound (II), wherein the 1,3-diketone compound is selected from The molar ratio of the diphenylamino-4-benzaldehyde, malononitrile and 1,3-diketone compound is 1:1:1; the amount of the dehydrating agent is 3%-20% of the reaction volume ratio; and the heating and stirring reaction is a stirring reaction at 60°C-80°C.

3. The preparation method according to claim 2, characterized in that: The synthesis reaction formula of triphenylamine compounds is:

4. Use of the triphenylamine compound or its salt according to claim 1 in the preparation of an antibacterial agent, wherein the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

5. An antibacterial agent, characterized in that The invention contains the triphenylamine compound or its salt as claimed in claim 1 as an active ingredient, and the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

6. The antibacterial agent according to claim 5, characterized in that The concentration of the triphenylamine compound or its salt is 4-16 μg / mL.